SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Dynavax DVAX -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (163)9/26/2018 11:35:08 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 184
 
There will also be updates for anti-PD-1 "progressors" (all at 8 mg, no 2 mg patients) and head and neck (full 8 mg cohort, n = 25 or 26, and 10-12 patients at 2 mg).

(HNSCC update at ACR had 18 patients at

So.... incremental updates, "naive" presentation didn't make plenary, and fog over SD-101 unlikely to clear, my opinion (please get your own!).



To: scaram(o)uche who wrote (163)10/20/2018 6:56:28 PM
From: tuck  Read Replies (2) | Respond to of 184
 
Just came across this:

HNSCC SD-101 TLR9 with Pembro in PD-1 naive pts

Duration of response not looking too good.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News